Sameek Roychowdhury

10.1k total citations · 2 hit papers
83 papers, 3.7k citations indexed

About

Sameek Roychowdhury is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Sameek Roychowdhury has authored 83 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 37 papers in Molecular Biology and 29 papers in Cancer Research. Recurrent topics in Sameek Roychowdhury's work include Fibroblast Growth Factor Research (27 papers), Cancer Genomics and Diagnostics (25 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (16 papers). Sameek Roychowdhury is often cited by papers focused on Fibroblast Growth Factor Research (27 papers), Cancer Genomics and Diagnostics (25 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (16 papers). Sameek Roychowdhury collaborates with scholars based in United States, Spain and Belgium. Sameek Roychowdhury's co-authors include Julie W. Reeser, Melanie A. Krook, Jharna Miya, Hui‐Zi Chen, Russell Bonneville, Lianbo Yu, Esko A. Kautto, Michele R. Wing, Richard Simon and Arul M. Chinnaiyan and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Sameek Roychowdhury

80 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Landscape of Microsatellite Instability Across 39 Cancer Types

2017 1.0k citations Russell Bonneville, Melanie A. Krook et al. profile →
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

2020 213 citations Melanie A. Krook, Julie W. Reeser et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sameek Roychowdhury United States	29	1.6k	1.3k	1.1k	848	774	83	3.7k
Hendrik‐Tobias Arkenau United Kingdom	34	2.3k 1.5×	1.5k 1.2×	769 0.7×	1.2k 1.4×	362 0.5×	214	4.1k
Steven J. Lemery United States	26	1.8k 1.2×	545 0.4×	782 0.7×	852 1.0×	613 0.8×	65	3.3k
Ignacio Garrido‐Laguna United States	32	3.1k 2.0×	1.8k 1.4×	1.5k 1.3×	1.1k 1.3×	493 0.6×	160	4.9k
Sabine Merkelbach‐Bruse Germany	35	1.4k 0.9×	1.1k 0.9×	985 0.9×	2.1k 2.5×	308 0.4×	174	4.5k
Andréa Varga France	33	3.0k 1.9×	1.2k 0.9×	547 0.5×	1.2k 1.5×	816 1.1×	107	4.6k
Paul Frankel United States	34	1.9k 1.3×	1.8k 1.4×	658 0.6×	967 1.1×	388 0.5×	214	4.1k
Gary A. Ulaner United States	43	1.6k 1.0×	1.4k 1.1×	849 0.7×	930 1.1×	237 0.3×	186	5.1k
Anand Mayakonda United States	22	1.4k 0.9×	2.4k 1.9×	1.7k 1.5×	1.9k 2.2×	565 0.7×	35	4.2k
David S. Rickman United States	34	1.4k 0.9×	2.8k 2.2×	1.6k 1.4×	1.6k 1.9×	496 0.6×	63	5.6k
Helen Mackay Canada	41	2.9k 1.8×	2.9k 2.2×	1.3k 1.1×	1.2k 1.4×	576 0.7×	185	7.1k

Countries citing papers authored by Sameek Roychowdhury

Since Specialization

Citations

This map shows the geographic impact of Sameek Roychowdhury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sameek Roychowdhury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sameek Roychowdhury more than expected).

Fields of papers citing papers by Sameek Roychowdhury

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sameek Roychowdhury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sameek Roychowdhury. The network helps show where Sameek Roychowdhury may publish in the future.

Co-authorship network of co-authors of Sameek Roychowdhury

This figure shows the co-authorship network connecting the top 25 collaborators of Sameek Roychowdhury. A scholar is included among the top collaborators of Sameek Roychowdhury based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sameek Roychowdhury. Sameek Roychowdhury is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saleh, Mansoor N., Minal Barve, Vivek Subbiah, et al.. (2024). Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies. ESMO Open. 9(7). 103625–103625. 4 indexed citations

Kaffenberger, Benjamin H., Catherine Chung, Eric Samorodnitsky, et al.. (2024). Myeloid neoplasm with histiocytosis and spleen tyrosine kinase fusion responds to fostamatinib. Haematologica. 109(11). 3816–3820. 1 indexed citations

Silverman, Ian M., Meijuan Li, Karthikeyan Murugesan, et al.. (2022). Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. Journal of Molecular Diagnostics. 24(4). 351–364. 8 indexed citations

Ramsey, Mitchell L., Rachel Pearlman, Laith Abushahin, et al.. (2022). Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. Familial Cancer. 22(1). 91–97. 23 indexed citations

Krook, Melanie A., Max Wilberding, Kelly M. Bailey, et al.. (2020). Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Molecular Cancer Therapeutics. 19(3). 847–857. 106 indexed citations

Bonneville, Russell, Michele R. Wing, Melanie A. Krook, et al.. (2020). Characterization of Clonal Evolution in Microsatellite Unstable Metastatic Cancers through Multiregional Tumor Sequencing. Molecular Cancer Research. 19(3). 465–474. 7 indexed citations

Wu, Christina, Terence M. Williams, Ryan Robb, et al.. (2020). Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clinical Cancer Research. 26(13). 3117–3125. 13 indexed citations

Abou‐Alfa, Ghassan K., Ivan Borbath, Allen Lee Cohn, et al.. (2020). 1014TiP PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements. Annals of Oncology. 31. S701–S702. 1 indexed citations

Krook, Melanie A., Hui‐Zi Chen, Julie W. Reeser, et al.. (2019). Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 22(4). 624–632. 5 indexed citations

10.

Tomšič, Jerneja, Ralf Bundschuh, Pamela Brock, et al.. (2019). Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers. Thyroid. 29(4). 523–529. 35 indexed citations

11.

Krook, Melanie A., et al.. (2018). Rapid Research Autopsy: Piecing the Puzzle of Tumor Heterogeneity. Trends in cancer. 5(1). 1–5. 11 indexed citations

12.

Javle, Milind, Robin Kate Kelley, Sameek Roychowdhury, et al.. (2018). Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Annals of Oncology. 29. viii720–viii720. 33 indexed citations

13.

Datta, Jharna, Senthilkumar Damodaran, Jharna Miya, et al.. (2017). Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. Molecular Cancer Therapeutics. 16(4). 614–624. 72 indexed citations

14.

Miya, Jharna, et al.. (2016). Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations. Journal of Visualized Experiments. 13 indexed citations

15.

Damodaran, Senthilkumar & Sameek Roychowdhury. (2015). Genomics and Precision Cancer Medicine. 11(2). 145–145. 1 indexed citations

16.

Damodaran, Senthilkumar, Jharna Miya, Esko A. Kautto, et al.. (2015). Cancer Driver Log (CanDL). Journal of Molecular Diagnostics. 17(5). 554–559. 36 indexed citations

17.

Raymond, Victoria M., Stacy W. Gray, Sameek Roychowdhury, et al.. (2015). Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories: Table 1.. JNCI Journal of the National Cancer Institute. 108(4). djv351–djv351. 72 indexed citations

18.

Simon, Richard & Sameek Roychowdhury. (2013). Implementing personalized cancer genomics in clinical trials. Nature Reviews Drug Discovery. 12(5). 358–369. 218 indexed citations

19.

Roychowdhury, Sameek & Moshe Talpaz. (2011). Managing resistance in chronic myeloid leukemia. Blood Reviews. 25(6). 279–290. 54 indexed citations

20.

Baiocchi, Robert A., Charles F. Eisenbeis, Sameek Roychowdhury, et al.. (2001). GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. Journal of Clinical Investigation. 108(6). 887–894. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact